JMP Securities analyst Liisa Bayko said BioCryst's BCX7353 showed an "impressive response in a meaningful proportion of patients" and tolerability that was much improved from the Phase 2 trial. She thinks today's greater than 50% pullback in BioCryst shares is an overreaction, stating that her research suggests that about 50% of the HAE market is not on a prophylaxis today. The analyst, who also sees patients being eager to try an oral option, said that BioCryst is conducting more pricing analysis to price below currently available injectables. Bayko keeps an Outperform rating and $18 price target on BioCryst shares, which are down $4.18 to $3.20 per share in afternoon trading.